Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Sepracor-Looks very promising -- Ignore unavailable to you. Want to Upgrade?

To: BMcV who wrote (1046)	7/23/1998 1:53:00 PM
From: BMcV	Respond to of 10280

12,500 went off at the bid, 58 7/8 Yikes! now 75,000 at the ask, 59 1/4! What a day! Huge blocks flying everywhere

To: BMcV who wrote (1046)	7/23/1998 2:57:00 PM
From: Biomaven	Respond to of 10280

Excellent summary, Bruce. A couple of small points I'd add: On Prozac, I think they're just playing poker, and making it very clear that they'll go it alone or with someone else if Lilly balks at their price. My guess is that Lilly will eventually sign up, which would be in both sides' interest. I'm continually astounded that new ICEs keep popping up in their portfolio. Their latest is a version of Risperidone, a very big, very new anti-psychotic. Of course this is very much still on patent, so there will only be a licensing deal with the current franchisee, and then only if there is some compelling advantage over the existing drug. (They didn't say what this might be). At very worst, it fills their distant pipeline. Peter